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A 69-year-old woman underwent thoracic computed tomography (CT), which revealed a nodule
in the superior segment of the right lower lobe. Transbronchial lung biopsy revealed small cell
lung cancer. No metastasis was detected. However, one month later, repeat CT showed
spontaneous regression of the tumor. We performed segmentectomy, which conﬁrmed that the
tumor was stage IA small cell lung cancer. The patient received adjuvant chemotherapy, with no
recurrence for 27 months. Spontaneous regression of small cell lung cancer is very rare. Our
treatment strategy may have contributed to a favorable prognosis.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Spontaneous regression (SR) of cancer is deﬁned as partial
or complete disappearance of malignant disease without
any medical treatment [1]. This phenomenon is rare,
especially in the case of small cell lung cancer (SCLC), with
very few reports in the literature to date [2–5]. The
prognosis of SCLC with SR is considered to be favorable.
However, there have been some reports of regrowth of SCLC
after SR [5]. Due to the rarity of SR of SCLC, treatment for this
condition has not been established yet..02.001
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.jp (A. Sano).A 69-year-old woman who gave a history of smoking
1 pack per day for 34 years was noted to have an abnormal
shadow on chest X-ray during a screening examination. The
patient was referred to our hospital. Thoracic computed
tomography (CT) revealed a nodule (16 mm 12 mm) in the
superior segment of the right lower lobe (Figure 1). There
was no lymphadenopathy. Transbronchial lung biopsy was
performed. Histological examination revealed SCLC
(Figure 2A). Pro-gastrin-releasing peptide (pro-GRP) was
211 pg/ml (normal value, less than 81.0 pg/ml) and
neuron-speciﬁc enolase (NSE) was 12.6 ng/ml (normal
value, less than 16.3 ng/ml). Positron emission tomography
(PET) and brain magnetic resonance imaging (MRI) showed
no evidence of metastasis. We diagnosed the patient with
T1aN0M0 stage IA SCLC. The patient's general health condi-
tion was good enough to tolerate surgery. Therefore,en access article under the CC BY-NC-ND license
Figure 1 (A) Thoracic computed tomography showing a shadow representing a mass (16 mm 12 mm, arrowheads) in the superior
segment of the right lower lobe. (B) Thoracic computed tomography, obtained 1 month after the ﬁrst scan, showing a decrease in
the size of the mass (arrowheads).
Figure 2 (A) Transbronchial lung biopsy specimen demonstrating mostly crushed small cell carcinoma cells (hematoxylin and eosin
stain,  200) (B) High-power magniﬁcation of the specimen obtained by segmentectomy, revealing the tumor to be small cell lung
cancer (hematoxylin and eosin stain,  200)
M. Inui et al.22surgical resection of the tumor was planned. On the day
before surgery, repeat CT showed spontaneous regression of
the tumor (10 mm 8 mm). The pro-GRP level had also
declined, to 67.6 pg/ml. Resection of the superior segment
of the right lower lobe and lymph node sampling were
performed as scheduled. The pathohistological diagnosis
was T1aN0M0 stage IA SCLC (Figure 2B). The patient
received 4 cycles of platinum-containing chemotherapy
(carboplatin+etoposide), but did not undergo prophylactic
cranial irradiation (PCI). For 27 months, serum levels of pro-
GRP and NSE have remained within normal limits and there
have been no evidence of recurrence to date.2. Discussion
Everson and Cole deﬁned SR of cancer is a complete or
partial disappearance of all or at least some relevant
disease that is either temporary or permanent in nature,
without any medical treatment or with treatment that is
considered inadequate to bring about the regression [1].
This phenomenon is very rare and has been described as
occurring no more than once in 60,000–100,000 cancer
patients [6]. SR is more rare in lung cancer than in othersolid tumors, such as renal cell carcinoma, neuroblastoma,
and malignant melanoma. Cole reported only 1 case of lung
cancer among 176 cases of SR [7]. Furthermore, there are
very few previous reports describing SR of SCLC.
The mechanisms underlying SR of cancer are controver-
sial. Possible mechanisms include apoptosis, immunological
and cytokine-mediated mechanisms, differentiation, hor-
monal mechanisms, inhibition of angiogenesis or telomer-
ase, and psychoimmunological mechanisms induced by
causative factors, such as infection, fever, drugs, radiation,
trauma, which includes surgery, hormones, pregnancy, and
carcinogens [6]. Several reports in the literature have
described the relationship between SR of SCLC and para-
neoplastic neuropathy [4].
According to the American College of Chest Physicians
Evidence-Based Clinical Practice guidelines, surgical resec-
tion is suggested over non-surgical treatment in patients
with clinical stage I SCLC. After surgery with curative
intent, platinum-based adjuvant chemotherapy is recom-
mended. When there is a complete or partial response to
initial therapy, PCI is also recommended [8].
The present patient certainly had stage IA SCLC, con-
ﬁrmed by clinical and pathological ﬁndings before and after
surgery. It is widely considered that SR of cancer carries a
23lung cancerfavorable prognosis, but there are some case reports of
regrowth of limited disease SCLC after SR. There is no
consensus on the best treatment. We performed surgical
resection with curative intent and administered 4 cycles of
platinum-based adjuvant chemotherapy (carboplatin and
etoposide). Considering the adverse side effects and favor-
able prognosis, we did not strongly recommend PCI to this
patient, opting instead for careful observation. This treat-
ment procedure may lead to a more favorable prognosis.
3. Conclusion
Because it is widely considered that SR of cancer carries a
favorable prognosis, surgery and adjuvant chemotherapy
without PCI may lead to a more favorable outcome for stage
I SCLC after SR.
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